2018 Fundraising
Invest now

1

1

1

Breakthrough innovation in the fight against pancreatic cancer

Breakthrough innovation in the fight against pancreatic cancer

CC&C is a Medtech start-up. We rely on the latest discoveries in the field of oncology and in particular physical oncology and mechanobiology, to develop a treatment against pancreatic cancer.

Learn more about our technology…

In 2016, we published our Proof of Concept in PlosOne. This experiment validated the action of mechanical stress on a grafted tumor in mice. This is the first time in the world that such a result is obtained on live animals, and not in cell cultures.

Read our article …

Today, our goal is to experimentally validate the action of our device on human pancreatic cancer grafted in mouse pancreas. To do this, we have initiated two partnerships, one in the United States with the prestigious Stanford University, the other in a European consortium around the Bichat Faculty of Medicine in Paris, a world leader in Digestive Oncology.

Learn more about our Proof of Efficacy…

Our medium-term strategy: to finish research within two years and move on to a human prototype, with the goal of a first human experiment in 2022.

Why such a rapid development?

What is Cell Constraint & Cancer ?

of research

raised in 2018

before placing on the market

subscribe to our capital increase

Invest in a breakthrough innovation, unique and patented.

Development faster than a drug.

Latest news from CC&C

Results for the second quarter 2018

- EUROPEAN GRANT APPLICATION FET OPEN: 1.8 MILLION EURO REQUESTED, RESPONSE ON OCTOBER 16TH, 2018 - AFTER STANFORD UNIVERSITY, NEW PARTNERSHIPS IN PERSPECTIVE On May 16th, we submitted an application for a grant of 1.8 million Euro from the European Commission as part...
Lire la suite

20 months of extra life for pancreatic cancer patients

In Chicago, on June 4th, was held the annual conference of the American Society of Clinical Oncology (ASCO), during which an interesting communication was made. The news comes from France, more precisely from Nancy. Already three years ago, the team of the Cancer...
Lire la suite

NanoStress: we answered the FET-Open call for projects

The FET-Open call of the European Commission finances disruptive innovation research projects capable of « changing the world ». We did not need it any less, so we submitted today a nomination file within the NanoStress consortium, in order to obtain the Proof of...
Lire la suite

12 + 3 =

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles

CELL CONTRAINT & CANCER
le Mas l’Hermite
331 chemin de la Poterie
f13280 Raphèle les Arles